WGWalter Gall

Walter Gall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Walter Gall has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of Cross-Sector Health Care Quality Indicators Based on Claims Data

    by Walter Gall, Hana Šinkovec, Alexander Niessner, Patrick Sulzgruber, Georg Heinze

    Quality indicators serve as a tool to measure and improve evidence-based health care. Often the transition from inpatient to outpatient care is not sufficiently included. The focus of this work was to develop and to evaluate methods to define relevant cross-sector quality indicators based on Austrian claims data, using myocardial infarction as tracer.

  • Open Access

    Integrating a New Dietetic Care Process in a Health Information System: A System and Process Analysis and Assessment

    by Gabriele Gäbler, Deborah Lycett, Walter Gall

    Managing routinely collected data in health care and public health is important for evaluation of interventions and answering research questions using “real life” and ”big data”. In addition to the technical requirements of information systems, both standardized terminology and standardized processes are needed. The aim of this project was to analyse and assess the integration of standardized terminology and document templates for a dietetic care process (DCP) into the health information system (HIS) in a hospital in Austria. Using an action research approach, the DCP was analysed through four expert interviews and the integration into the HIS through two expert interviews with observations. Key strengths and weaknesses for the main criteria (“integration of the ICF catalogue”, “adaption of the document templates”, “adaption of the DCP”, and the “adaption of the user authorizations”) were presented and proposals for improvement given. The system and process integration of the DCP is possible, and the document templates can be adapted with the software currently in use. Although an increase in resources and finances required is to be expected initially, the integration of a standardized dietetic terminology in combination with a standardized process is likely to improve the quality of care and support outcomes management and research.


  • Open Access

    Use and overuse of triptans in Austria – a survey based on nationwide healthcare claims data

    by Karin Zebenholzer, Walter Gall, Christian Wöber

    To evaluate triptan use and overuse as well as prescription patterns in Austria based on a nationwide healthcare database because data on triptan use and overuse in Austria is missing. We included all persons insured with one of 19 Austrian social security institutions in 2007. Inclusion criteria comprised an age of 18–99 years, known sex, and receipt of insurance benefits. We defined triptan use as ≥1 package of a triptan dispensed in 2007 and triptan overuse as ≥30 defined daily doses dispensed in at least one quarter. Out of 8.295 million inhabitants in Austria, 7,426,412 persons (89.5%) were insured with a social insurance carrier and 5,918,487 persons of those insured (79.7%) fulfilled the inclusion criteria. Among the latter 33,062 persons (0,56%) were triptan users and 1970 (0.033%) were triptan overusers. The estimated proportion of persons with migraine using a triptan was less than 6%. Among users 5.9% were overusers of whom 55% overused triptans in ≥2 quarters of 2007. The median number of days of sick-leave was higher in triptan users than in non-users: due to any reason of sick-leave 12 vs. 10, p < 0.001, due to migraine 3 vs. 2, p < 0.001. The proportion of hospital admissions did not differ between triptan users and non-users. The rate of triptan use is low in Austria but triptan users are at risk for triptan overuse. In triptan users more days of sick-leave and the same proportion of hospital admissions as in the older non-users suggest poorer health.


    • 1 January 2016
      • Vol. 223, 253-8

    How Many Patients Could Benefit From Pre-emptive Pharmacogenomic Testing and Decision Support? A Retrospective Study Based on Nationwide Austrian Claims Data.

    by Wolfgang Kuch, Christoph Rinner, Walter Gall, Matthias Samwald

    Pre-emptive pharmacogenetic (PGx) testing combined with clinical decision support is a promising new strategy for making pharmacotherapy safer and more effective. To estimate the number of patients whose therapies could be guided by this approach, we analysed claims data for patients in Austria in the years 2006 and 2007. We calculated the number of patients receiving one or several drugs for with pharmacogenomic guidelines are available (PGx drugs). The cohort consisted of 6,761,034 patients and was split into four age groups. Patients in the age group >= 65 were prescribed the most PGx drugs, with 72% of the patients receiving at least one PGx drug. 39.1% of all people over 65 received at least one drug metabolized by the three most frequent cytochrome P450 enzymes. Our data indicate that a sizable fraction of elderly patients could profit from the implementation of pre-emptive PGx testing and decision support.


  • Open Access

    A Diabetes Self-Management Prototype in an AAL-Environment to Detect Remarkable Health States

    by Schindelboeck Denise, Praus Friedrich, Gall Walter

    Every year life span is increasing and simultaneously the proportion of people with one or more chronic diseases. This paper presents an implementation of a prototype with a decision tree to detect dangerous health conditions for Diabetes Type 1 and Diabetes Type 2. With the information we collect from Personal Health Devices and data from the Active-Assisted-Living environment, we are in the position to customize thresholds and to get individual results. With the help of a modified Glucose-Insulin Model (based on the minimal model of Stolwijk & Hardy) we predicted the future glucose concentration of the patient. We validated our model with an intention-to-treat pilot study including 8 subjects and obtained a significantly better (p < 2.2−16) result than the original model.

  • Open Access

    Effects of Shared Electronic Health Record Systems on Drug-Drug Interaction and Duplication Warning Detection

    by Christoph Rinner, Wilfried Grossmann, Simone Katja Sauter, Michael Wolzt, Walter Gall

    Shared electronic health records (EHRs) systems can offer a complete medication overview of the prescriptions of different health care providers. We use health claims data of more than 1 million Austrians in 2006 and 2007 with 27 million prescriptions to estimate the effect of shared EHR systems on drug-drug interaction (DDI) and duplication warnings detection and prevention. The Austria Codex and the ATC/DDD information were used as a knowledge base to detect possible DDIs. DDIs are categorized as severe, moderate, and minor interactions. In comparison to the current situation where only DDIs between drugs issued by a single health care provider can be checked, the number of warnings increases significantly if all drugs of a patient are checked: severe DDI warnings would be detected for 20% more persons, and the number of severe DDI warnings and duplication warnings would increase by 17%. We show that not only do shared EHR systems help to detect more patients with warnings but DDIs are also detected more frequently. Patient safety can be increased using shared EHR systems.


    • 1 January 2012
      • Vol. 180, 667-71

    Fragmentation of diabetes treatment in Austria - an indicator for the need for shared electronic health record systems.

    by Georg Duftschmid, Wolfgang Dorda, Gottfried Endel, Karl Fröschl, Walter Gall, Wilfried Grossmann, Milan Hronsky

    Shared electronic health record (EHR) systems aim to support continuity of care within the joint treatment of a patient by a community of cooperating care providers. By analyzing the fragmentation of care of Austrian diabetes patients, we aim to find evidence whether there is actually a need for shared EHR systems in this context. Our results show that almost three quarters of the observed diabetes patients visit two or more different care providers during their diabetes-related visits. Overall, our findings strongly support the demand for shared EHR systems for the treatment of diabetes patients.


    • 1 January 2008
      • Vol. 136, 425-30

    Analysis of EHRs for research, quality management and health politics.

    by Walter Gall, Wilfried Grossmann, Georg Duftschmid, Thomas Wrba, Wolfgang Dorda

    Lifelong electronic health records can supply valuable information for research, quality management and health politics in addition to supporting treatment of patients. Based on experiences with scientific data analysis in a university hospital environment, requirements on cross-institutional analysis of electronic health records in a healthcare system are discussed. The concept of archetypes can play a key role in this context. Archetypes can be utilized in data analysis for visualization, semantic linkage and finally for standardized data transfer.

  • Management of data from clinical trials using the ArchiMed system

    by Georg Duftschmid, Walter Gall, Ernst Eigenbauer, Wolfgang Dorda

    Clinical trials constitute a key source of medical research and are therefore conducted on a regular basis at university hospitals. The professional execution of trials requires, among other things, a repertoire of tools that support efficient data management. Tasks that are essential for efficient data management in clinical trials include the following: the design of the trial database , the design of electronic case report forms , recruiting patients , collection of data , and statistical analysis . The present article reports the manner in which these tasks are supported by the ArchiMed system at the University of Vienna and Graz Medical Schools. ArchiMed is customized for clinical end users, allowing them to autonomously manage their clinical trials without having to consult computer experts. An evaluation of the ArchiMed system in 12 trials recently conducted at the University of Vienna Medical School shows that the individual system functions can be usefully applied for data management in clinical trials.